S9. Conservative management of atypical endometrial hyperplasia and early invasive carcinoma with intrauterine levonorgestrel: a progesterone receptor study”  by unknown
S9. CONSERVATIVE MANAGEMENT OF ATYPICAL ENDOMETRIAL
HYPERPLASIA AND EARLY INVASIVE CARCINOMA WITH
INTRAUTERINE LEVONORGESTREL: A PROGESTERONE
RECEPTOR STUDY
Tjalmaa WAA, Janssensb D, Wildemeerschc D, Colpaertd C, Wattya K.
aDepartment of Gynecology and Gynecological Oncology, University Hospital
Antwerpen, University Antwerpen, Belgium; bDepartment of Gynecology,
Turnhout, Belgium; cContrel Research, Technology Park, Ghent (Zwijnaarde)
Belgium; dDepartment of Pathology, University Hospital Antwerpen, University
Antwerpen, Belgium
Introduction: Promising clinical results with the levonorgestrel–intrauterine drug
delivery system (LNG-IUS) in women with atypical endometrial hyperplasia
have been published previously.1 This treatment could, therefore, be useful for
patients with atypical hyperplasia or early endometrial malignancy who are poor
surgical candidates or who do not want to be operated upon, e.g., patients
wishing to preserve their fertility. However, a small number of women treated
with systemic progestogen show persistence or progression of the condition
which has been attributed to the non-availability of progesterone receptors (PR)
at treatment initiation and/or to an alteration in regular progesterone function.2
Several research groups have noted a downregulation of PR in LNG-IUS-
treated endometrium in pre-menopausal fertile women.2,3 The aim of this study
was to analyse the feasibility of such a treatment with a novel, frameless LNG-
IUS and the potential signiﬁcance of quantitative PR assessment in this
management.
Patients and methods: Eight post-menopausal women (7 with atypical endome-
trial hyperplasia and 1 with endometrial cancer International Federation of
Gynecology and Obstetrics (FIGO) stage 1A) were treated with a LNG-IUS,
releasing 14 g of LNG/day. Mean age was 58 years (range 46-58 years) and mean
Fig. 1. Atypical endometrial hyperplasia prior to treatment, showing immunoreactivity for progesterone receptor (PR) in almost all epithelial cells (original magniﬁcation
200x).
Fig. 2. Endometrium of the same patient during treatment with the LNG-IUS. The endometrium shows atrophy with low expression of progesterone receptor in the
epithelial cells of the atrophic glands, but preserved immunoreactivity in many decidualised stromal cells (original magniﬁcation 200x).
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follow-up 29 months (range 11-51 months). All had clinical examination,
transvaginal ultrasound (TVU), D&C or pipelle biopsy and consented to receive
treatment. The use of the LNG-IUS was approved by the Ethics Committee of
the University of Ghent, Belgium. Patients were seen on a regular basis every 3–6
months including clinical examination, TVU and endometrial biopsy.
To determine the endometrial PR status, paraﬃn-embedded tissue sections were
immunohistochemically stained with a mouse monoclonal antibody (NCL-
PGR-312, Novo Castra Laboratories, Newcastle-upon-Tyne, UK). The per-
centage of immunoreactive nuclei was scored, both in the endometrial epithelium
and stroma.
Results: At study initiation, all eight women showed expression of PR in the
epithelial cells, ranging from 50% to 95% (Fig. 1). The percentage declined over
time during treatment (range 5–50%) (Fig. 2). No recurrence or progression of
disease was noticed in any of the women. The endometrial histology specimen
showed profound endometrial suppression with glandular atrophy and stromal
decidualisation in all women.
Discussion: Intrauterine progestogen delivery, particularly LNG, acts through-
out the whole thickness of the mucosa caused by the high tissue concentra-
tions3 and could, therefore, be a promising alternative treatment. Continuous
intrauterine progestogen administration could enhance the success rate. The
signiﬁcant reduction of the PR expression observed during treatment with the
LNG-IUS in our study appears to be a marker for the strong antiproliferative
eﬀect of the hormone at a cellular level resulting in an inhibition of
oestrogen bioactivity and endometrial suppression. In the absence or where
there is a low content of PRs before treatment, this cascade of events may be
hindered and may explain why, at least in some cases, persistence or
progression of disease occurs. Women with this condition should be carefully
followed.
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